Molecular probes for P2X7 receptor studies

被引:41
作者
Gunosewoyo, Hendra
Coster, Mark J.
Kassiou, Michael [1 ]
机构
[1] Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia
[2] Univ Sydney, Brain & Mind Res Inst, Sch Med Radiat Sci, Sydney, NSW 2050, Australia
关键词
ATP; purinergic; P2X(7); microglia; antagonist; KN-62; adamantyl amides; tetrazoles;
D O I
10.2174/092986707780831023
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The ionotropic P2X(7) receptor (P2X(7)R) has become the focus of intense research interest for a number of reasons: i) it is a cation selective ion channel that is modulated by extracellular ATP. Upon stimulation by high concentrations of ATP it generates a non-selective membrane pore which is permeable to hydrophilic molecules with molecular weight up to 900 Da. ii) Though its physiological function is yet to be fully understood, there is high P2X7R expression in microglia. Importantly, this implies a pivotal role for the P2X7R in neuro-inflammatory and -degenerative processes, In addition, P2X(7)R-stimulated release of traditional neurotransmitters in the brain, such as glutamate and GABA, further supports the involvement of P2X7R in neuroinflammatory and -degenerative processes. P2X(7)-knockout animals are also found to be resistant to inflammation and neuropathic pain, which suggests that P2X7 antagonists could potentially serve as all-purpose analgesics. Recent advances in the development of P2X(7)R ligands have resulted in identification of several different classes of P2X7R antagonists, including A,rp analogues (oxidized ATP), dyes (Brilliant Blue G), tyrosine derivatives (KN-62 and KN-04), cyclic imides, adamantane and benzamide derivatives. A KN-62 related radioligand has also recently been reported for use in receptor binding assays. A more extensive range of potent, selective P2X7R ligands is required for a better understanding of the cascade of cellular processes associated with the P2X(7)R. This article will review P2X(7)R ligands discovered to date, together with their biological activity and therapeutic potential.
引用
收藏
页码:1505 / 1523
页数:19
相关论文
共 183 条
[1]   International union of pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy [J].
Abbracchio, Maria P. ;
Burnstock, Geoffrey ;
Boeynaems, Jean-Marie ;
Barnard, Eric A. ;
Boyer, Jose L. ;
Kennedy, Charles ;
Knight, Gillian E. ;
Fumagalli, Marta ;
Gachet, Christian ;
Jacobson, Kenneth A. ;
Weisman, Gary A. .
PHARMACOLOGICAL REVIEWS, 2006, 58 (03) :281-341
[2]  
Abbracchio MP, 1996, DRUG DEVELOP RES, V39, P393, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<393::AID-DDR21>3.0.CO
[3]  
2-1
[4]   P2X7 receptor: Death or life? [J].
Adinolfi E. ;
Pizzirani C. ;
Idzko M. ;
Panther E. ;
Norgauer J. ;
Di Virgilio F. ;
Ferrari D. .
Purinergic Signalling, 2005, 1 (3) :219-227
[5]   Novel P2X7 receptor antagonists [J].
Alcaraz, L ;
Baxter, A ;
Bent, J ;
Bowers, K ;
Braddock, M ;
Cladingboel, D ;
Donald, D ;
Fagura, M ;
Furber, M ;
Laurent, C ;
Lawson, M ;
Mortimore, M ;
McCormick, M ;
Roberts, N ;
Robertson, M .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (22) :4043-4046
[6]  
ASTRAZENECA AB, 2005, Patent No. 2005014529
[7]  
ASTRAZENECA AB, 2005, Patent No. 2005009968
[8]   Synthesis and biological activity of N-arylpiperazine-modified analogues of KN-62, a potent antagonist of the purinergic P2X7 receptor [J].
Baraldi, PG ;
Nuñez, MD ;
Morelli, A ;
Falzoni, S ;
Di Virgilio, F ;
Romagnoli, R .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (08) :1318-1329
[9]   Agonists and antagonists acting at P2X7 receptor [J].
Baraldi, PG ;
Di Virgilio, F ;
Romagnoli, R .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (16) :1707-1717
[10]   Synthesis of conformationally constrained analogues of KN62, a potent antagonist of the P2X7-receptor [J].
Baraldi, PG ;
Romagnoli, R ;
Tabrizi, MA ;
Falzoni, S ;
Di Virgilio, F .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (07) :681-684